Jiyuan Medical Secures Tens of Millions of RMB in Series A Funding to Accelerate Global Expansion of ARMI® Disposable Hysteroscopy System

VCBeat has learned that Jiangsu Jiyuan Medical Technology Co., Ltd. (Jiyuan Medical) recently announced the successful completion of its Series A financing, raising tens of millions of yuan, which injects strong momentum into the company’s development. The round was led by Shanghai Sunland Investment Management Co., Ltd. (Sunland Capital), with Qingzheng Capital participating as a co-investor. The funds will accelerate Jiyuan Medical’s R&D of new products, regulatory registration and market launch, as well as global promotion, laying a solid foundation for the company’s future growth.

As an innovative medical enterprise specializing in the field of disposable electronic hysteroscopes, Jiangsu Jiyuan Medical Technology Co., Ltd. has achieved remarkable development milestones over the past five years since its establishment in 2017. The company has secured dozens of patents in areas such as image processing, software, algorithms, electronic engineering, structural design, and imaging systems, and has established a comprehensive operational and production platform.

Current product offerings include the ARMI disposable electronic hysteroscope, disposable hysteroscopic imaging catheter, GQJ medical endoscope image processor, and disposable accessory instruments for endoscopy. Integrated with its comprehensive disposable gynecological endoscopy solution, the product line has entered the commercialization phase.

Jiyuan Medical is committed to becoming a global leader in the field of disposable electronic hysteroscopes by prioritizing quality, driving continuous innovation, and maintaining professional dedication. Its independently developed ARMI disposable electronic hysteroscope, characterized by its lightweight operation, clear visualization, and superior performance, offers both usability and accessibility, earning widespread recognition and acclaim from healthcare professionals.

As one of the earliest disposable electronic hysteroscopes launched in the industry, the ARMI series has obtained registration certifications from China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). This not only signifies that the ARMI series was among the first disposable electronic hysteroscope products to enter the market, but also demonstrates Jiangsu Jiyuan Medical Technology Co., Ltd.’s technical prowess and market competitiveness in this field. By securing a strategic advantage in technological competition, the ARMI series has garnered significant market attention and recognition. Leveraging its top-tier R&D capabilities and professional team, Jiangsu Jiyuan Medical has also showcased substantial commercial potential.

To date, Jiangsu Jiyuan Medical Technology Co., Ltd. has completed nearly 4,000 clinical trials in over 300 hospitals worldwide, with its quality and efficacy receiving widespread acclaim from physicians. Professor Cao Zeyi, a renowned gynecological expert and former Vice Minister of the Ministry of Health, who serves as a medical advisor to Jiyuan Medical, hailed the ARMI disposable hysteroscope as a major revolution in medicine. The ARMI disposable hysteroscope is clinically equivalent to reusable hysteroscopes, eliminates the risk of cross-infection, offers convenience and ease of operation, and enables consecutive surgeries. Furthermore, both the equipment procurement cost and the consumable usage cost are significantly lower than those of reusable products, making it affordable for hospitals and accessible to patients. This innovation brings hope to a broader patient population, allowing more patients and families to benefit from the precision and minimally invasive care enabled by technological advancements.

This Series A financing round further validates Jiangsu Jiyuan Medical Technology Co., Ltd.’s market influence and development potential. The funds will be primarily used to accelerate the research, development, and commercialization of new products, including clinical trials, regulatory registration and market approval, as well as global promotion and sales. Jiangsu Jiyuan Medical will continue to refine its product portfolio and consistently enhance product quality and technological capabilities to meet the demands of the global market. The completion of this financing round will further strengthen the company’s financial position and competitive advantage, laying a solid foundation for its rapid future growth.

Regarding this financing round,Zhang Yunfei, Chairman of Jiyuan Medical“He stated: ‘Disposable endoscopes are innovative products born from the convergence of the technological and industrial revolutions. Currently, Chinese enterprises and foreign companies stand on the same starting line. In the field of gynecology, Jiyuan Medical is even at the forefront globally, competing alongside leading international enterprises. Over the past six years since its establishment, Jiangsu Jiyuan Medical Technology Co., Ltd. has received strong support from all sectors of society. An increasing number of talented professionals have joined Jiyuan, and a growing base of customers has chosen our solutions. The journey thus far has been fraught with challenges, yet we have also been immensely fortunate. We extend our heartfelt gratitude to all organizations and friends who have trusted, supported, and assisted Jiyuan. For the successful completion of this Series A financing round, we particularly thank Shanghai Sunland Investment Management Co., Ltd. (Shanlan Capital) and Qingzheng Capital for their choice and confidence in Jiyuan Medical, as well as our team for their dedication and hard work. Jiyuan Medical is committed to going all out to accelerate development and live up to expectations.’”

Gu Shenghan, Executive Director of Sunland CapitalIt stated: “Disposable hysteroscopes align with the clinical concept of ‘integrated outpatient diagnosis and treatment’ and the industry trend toward ‘disposable endoscopic consumables,’ significantly improving clinical diagnostic and therapeutic efficiency. Jiangsu Jiyuan Medical Technology Co., Ltd.’s disposable hysteroscope closely addresses actual clinical needs from the product design stage, has accumulated robust evidence-based medical data through thousands of comparative studies against imported reusable hysteroscopes, and has laid a solid foundation for market access and commercialization as an industry pioneer. The company’s founding team demonstrates high execution efficiency, strong learning and adaptive capabilities, and a pronounced pragmatic entrepreneurial spirit. We are optimistic about the company’s strategic goal of creating a comprehensive solution for hysteroscopic surgery and look forward to Shanghai Sunland Investment Management Co., Ltd.’s industrial resources helping the company benefit more patients with additional high-quality innovative products.”

Li Xuesong, Chairman of Qingzheng CapitalIt stated: “Disposable hysteroscopes effectively address the cross-infection issues associated with traditional reusable hysteroscopes. Featuring a small diameter, wide field of view, and dual-side illumination, disposable hysteroscopes enable precise localization and direct access to lesions. This results in minimal invasiveness, faster recovery, and significant reduction in patient discomfort during treatment. Furthermore, through iterative upgrades, the cost of disposable hysteroscopes has become more affordable, offering numerous benefits to patients. After clinical trials at multiple Grade A tertiary hospitals, Jiangsu Jiyuan Medical Technology Co., Ltd.’s disposable hysteroscope demonstrated excellent performance and gained widespread recognition among major hospitals. Jiyuan Medical’s products have been included in the medical insurance catalogs of various provinces. We believe that Jiyuan Medical’s products will continue to bring greater benefits to more patients in the future.”

Looking ahead, Jiangsu Jiyuan Medical Technology Co., Ltd. will remain committed to innovation and R&D, continuously enhancing the technical sophistication and quality standards of its products to meet the demands of the global healthcare market. The company will continue to expand its global presence, strengthen international cooperation, and promote the widespread adoption and application of disposable electronic hysteroscopes worldwide. Upholding the philosophy of “quality as the foundation and innovation as the core,” Jiyuan Medical will make greater contributions to the development of the healthcare industry and provide patients with safer and more convenient medical solutions.

With the successful completion of this round of financing, Jiangsu Jiyuan Medical Technology Co., Ltd. will usher in a new stage of development. The company will adopt a more proactive approach to accelerate product innovation and market promotion, thereby facilitating the modernization and upgrading of the healthcare industry. We are confident that, through global collaboration and concerted efforts in the medical field, Jiyuan Medical will emerge as an industry leader and make even greater contributions to human health.”

Shanlan Capital, established in 2014, is a specialized healthcare investment fund focusing on early-stage and growth-stage investments in the medical health industry. It concentrates on high-growth medical subsectors such as medical devices, in vitro diagnostics (IVD), and biopharmaceuticals, and has invested in more than 50 leading healthcare companies. The core team of Shanlan Capital comprises founders of publicly listed companies with over two decades of industry experience in the healthcare sector, as well as top-tier professionals in biotechnology and medical equipment. With profound understanding and extensive experience in the fundamental nature of healthcare subsectors and the long-term development trends of the industry, the team provides precise and efficient support to accelerate the rapid growth of its portfolio companies.

Qingzheng Capital is a leading professional private equity fund management institution in China, established in April 2015. Founded by a team of seasoned veterans from the venture capital industry, Qingzheng Capital adheres to the principle of “upholding integrity and fostering innovation,” empowering technology-driven enterprises to achieve rapid growth.

Since its establishment, the company has been deeply rooted in China’s high-growth industries, selectively investing in leading, high-quality enterprises. By leveraging capital empowerment and providing services such as corporate financing, consulting, and management, it supports companies in deeply integrating into the industrial chain and enhancing their competitiveness. Over the years, Qingzheng Capital has invested in more than 20 domestic high-growth enterprises, helping them strengthen their core capabilities.